Molbio Diagnostics' IPO: A High-Risk Opportunity for Investors

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is preparing for an initial public offering (IPO) aimed at raising ₹940 crore. The company plans to secure ₹200 crore through a fresh issuance of shares to bolster its capital expenditures. Additionally, it intends to reduce promoter stake by generating ₹740 crore through an offer for sale, which will decrease the promoter group's stake from 46.6% to 43%.

Global Reach and Revenue Drivers

With six manufacturing facilities across India, Molbio serves clients in over 90 countries, including government health programs and international healthcare organizations. The company has experienced significant revenue growth, largely driven by its tuberculosis diagnostic test kits. These kits account for a substantial portion of its sales, with nearly 70% of the revenue stemming from diagnostic test kits for tuberculosis.

Molbio's 'Truenat' platform, a portable diagnostics system, is designed to deliver accurate test results in under an hour, catering to resource-limited settings. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, along with radiology, digital pathology, and breast health screening solutions via subsidiaries and strategic collaborations.

Financial Performance and Valuation

Between FY24 and FY26, Molbio's revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore, while net profit soared by 40.2% annually to ₹164.1 crore. The company's earnings before interest, tax, depreciation, and amortization (EBITDA) rose by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.

On a year-on-year basis in FY26, revenue jumped by 41.7%, EBITDA rose by 27.9%, and net profit grew by 18.4%. Molbio is targeting a price-earnings (P/E) multiple of up to 57, a figure that aligns with other healthcare diagnostics and medical device companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples between 54 and 81.

Investment Considerations

Molbio's reliance on a few major clients, which contribute over half of its revenue, indicates customer concentration risks. However, its robust growth trajectory and innovative diagnostic solutions present a compelling opportunity for investors with a high-risk appetite seeking long-term growth.

Founded in 2000, Molbio has established itself in the research, development, and manufacturing of diagnostic solutions for both infectious and non-communicable diseases. Government and international aid agencies are significant contributors to its revenue, accounting for over four-fifths of its income.